Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $160
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $145 to $160.
Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $145 to $160.